MDS Cytogenetic Scoring System
| Prognostic subgroups, % of patients . | Cytogenetic abnormalities . | Median survival,* y . | Median AML evolution, 25%,* y . | Hazard ratios OS/AML* . | Hazard ratios OS/AML† . |
|---|---|---|---|---|---|
| Very good (4%*/3%†) | −Y, del(11q) | 5.4 | NR | 0.7/0.4 | 0.5/0.5 |
| Good (72%*/66%†) | Normal, del(5q), del(12p), del(20q), double including del(5q) | 4.8 | 9.4 | 1/1 | 1/1 |
| Intermediate (13%*/19%†) | del(7q), +8, +19, i(17q), any other single or double independent clones | 2.7 | 2.5 | 1.5/1.8 | 1.6/2.2 |
| Poor (4%*/5%†) | −7, inv(3)/t(3q)/del(3q), double including −7/del(7q), complex: 3 abnormalities | 1.5 | 1.7 | 2.3/2.3 | 2.6/3.4 |
| Very poor (7%*/7%†) | Complex: > 3 abnormalities | 0.7 | 0.7 | 3.8/3.6 | 4.2/4.9 |
| Prognostic subgroups, % of patients . | Cytogenetic abnormalities . | Median survival,* y . | Median AML evolution, 25%,* y . | Hazard ratios OS/AML* . | Hazard ratios OS/AML† . |
|---|---|---|---|---|---|
| Very good (4%*/3%†) | −Y, del(11q) | 5.4 | NR | 0.7/0.4 | 0.5/0.5 |
| Good (72%*/66%†) | Normal, del(5q), del(12p), del(20q), double including del(5q) | 4.8 | 9.4 | 1/1 | 1/1 |
| Intermediate (13%*/19%†) | del(7q), +8, +19, i(17q), any other single or double independent clones | 2.7 | 2.5 | 1.5/1.8 | 1.6/2.2 |
| Poor (4%*/5%†) | −7, inv(3)/t(3q)/del(3q), double including −7/del(7q), complex: 3 abnormalities | 1.5 | 1.7 | 2.3/2.3 | 2.6/3.4 |
| Very poor (7%*/7%†) | Complex: > 3 abnormalities | 0.7 | 0.7 | 3.8/3.6 | 4.2/4.9 |